Adagene (ADAG)

Executive Summary

Adagene is a clinical-stage biotechnology company leveraging proprietary AI-powered platforms to develop novel antibody-based immunotherapies for cancer. Its pipeline spans nine candidates, including masked therapeutic antibodies designed to enhance tumor targeting and immune modulation. The lead program, ADG126 (a masked anti-CTLA-4 antibody), is in a Phase 2 trial for locally advanced colorectal cancer, with recruitment initiated in April 2025. Additionally, ADG206 (a conditionally activated antibody) is in Phase 1 for advanced solid tumors, with expected completion in August 2026. Despite early-stage pipeline risks, Adagene's differentiated technology and focus on precision immunotherapies position it for potential value inflection points from upcoming clinical data.

Upcoming Catalysts (preview)

• H2 2026ADG126 Phase 2 interim data in colorectal cancer60% success
• Q3 2026ADG206 Phase 1 data in advanced solid tumors20% success
• 2026Potential partnership or licensing deal for pipeline assets30% success